Juvenile Idiopathic Arthritis (JIA) Registry

NCT ID: NCT00783510

Last Updated: 2025-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

849 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-07-11

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This registry will assess the incidence and rate of Humira (monotherapy or combination therapy with MTX) or MTX observational and treatment-emergent SAEs, Adverse Events of Special Interest (AESI) and Pregnancy in patients diagnosed with moderately to severely active polyarticular or polyarticular-course JIA through Year 5. From Year 6 through Year 10 SAEs, a subset of AESI that includes congestive heart failure (CHF), malignancies, AEs at least possibly related to and/or leading to discontinuation of registry treatment and pregnancies will be collected. For JIA patients 2 to\< 4 years of age in countries with available local approval for this group of patients at the time of consent to the registry, emergent AESI, SAEs and pregnancy (at the age when a patient can become pregnant) will be collected for the full 10 years. The approved age range for HUMIRA in the U.S., European Union (EU) and in Australia is 4 years of age and older, and recent approval in EU for JIA patients 2 to \< 4 years of age.

Patients who discontinue from the registry before 10 years will be offered to participate in the direct to Health Care Provider follow-up process, as allowed by local regulations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Juvenile Idiopathic Arthritis JIA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HUMIRA® Treatment Arm

For patients taking HUMIRA®

adalimumab

Intervention Type BIOLOGICAL

As prescribed by treating physician

Methotrexate Treatment Arm

For patients taking Methotrexate

Methotrexate

Intervention Type DRUG

As prescribed by treating physician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adalimumab

As prescribed by treating physician

Intervention Type BIOLOGICAL

Methotrexate

As prescribed by treating physician

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HUMIRA® MTX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For a patient enrolling into the HUMIRA® arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting \>= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who has been prescribed HUMIRA® therapy according to the local approved HUMIRA® product labeling and meets one of the following criteria:
* Enrolled patients are 4 to 17 years of age as per approved HUMIRA® product label with the addition of JIA patients 2 to \< 4 years of age in countries with available local approval for this group of patients at the time of consent to the registry.
* Newly initiated (within 24 months of registry entry) on HUMIRA® therapy and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy, and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy;
* Or is entering after participation (within 24 months of registry entry or, if longer, continuously treated at the same site) in an AbbVie Humira sponsored study, regardless of age or the number of joints with symptoms of JIA, and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide available source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy.
* For a patient enrolling into the MTX arm; a pediatric patient diagnosed at any time with moderately to severely active polyarticular or polyarticular-course JIA (defined as arthritis affecting \>= 5 joints at the time of diagnosis of polyarticular or polyarticular-course JIA) who is prescribed MTX therapy alone or in combination with other disease modifying anti-rheumatic drugs (DMARDs) according to the local product labeling (initiated treatment within 24 months of registry entry) and has received continuous therapy and the physician can available provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of therapy.
* Parent or guardian has voluntarily signed and dated an informed consent/patient authorization form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) if applicable according to local law, after the nature of the registry has been explained and the patient's parent or legal guardian has had the opportunity to ask questions. Pediatric patients will be included in all discussions as per applicable local regulations in order to obtain verbal or written assent.

Exclusion Criteria

* Patients should not be enrolled into the HUMIRA® or Methotrexate (MTX) arm if they cannot be prescribed and treated in accordance with the approved local HUMIRA® and/or with the local MTX product label
* Patients should not be enrolled into the HUMIRA® or MTX arm if they require on-going treatment with Kineret® (anakinra), Orencia® (abatacept), Rituxan® (rituximab), Enbrel® (etanercept), and Remicade® (infliximab), or any other approved biologic agents or investigational agents.
* Patients should not be enrolled into the MTX arm if they have had prior treatment with any investigational agent or anti-rheumatic biologic therapy such as, but not limited to, Orencia® (abatacept), Enbrel® (etanercept), Remicade® (infliximab), Rituxan® (rituximab), or Actemra® (tocilizumab)
Minimum Eligible Age

2 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ Arthritis and Rheumotology Research, PLLC /ID# 21023

Phoenix, Arizona, United States

Site Status

Catalina Pointe Clinical Research /ID# 40227

Tucson, Arizona, United States

Site Status

Arkansas Children's Hospital /ID# 23505

Little Rock, Arkansas, United States

Site Status

Children's Hospital Los Angeles /ID# 24386

Los Angeles, California, United States

Site Status

Children's National Medical Center /ID# 23506

Washington D.C., District of Columbia, United States

Site Status

Duplicate_Arthritis Associates South FL /ID# 17001

Delray Beach, Florida, United States

Site Status

Ann & Robert H Lurie Children's Hospital of Chicago /ID# 20966

Chicago, Illinois, United States

Site Status

The University of Chicago Medical Center /ID# 21981

Chicago, Illinois, United States

Site Status

Methodist Medical Group Rheum /ID# 46343

Peoria, Illinois, United States

Site Status

Indiana University /ID# 11421

Indianapolis, Indiana, United States

Site Status

University of Louisville /ID# 23507

Louisville, Kentucky, United States

Site Status

Arthritis Care Spec. of MD /ID# 21961

Ellicott City, Maryland, United States

Site Status

Tufts Medical Center /ID# 21965

Boston, Massachusetts, United States

Site Status

Creighton Univ Med Ctr /ID# 11423

Omaha, Nebraska, United States

Site Status

St. Barnabas Ambulatory Care /ID# 21025

West Orange, New Jersey, United States

Site Status

North Shore University Hospital /ID# 21022

New Hyde Park, New York, United States

Site Status

University of Rochester Medical Center /ID# 20967

Rochester, New York, United States

Site Status

New York Medical College /ID# 21964

Valhalla, New York, United States

Site Status

Duke Cancer Center /ID# 22904

Durham, North Carolina, United States

Site Status

Bone Spine Sports/Medctr One /ID# 21962

Bismarck, North Dakota, United States

Site Status

Akron Children's Hospital /ID# 22907

Akron, Ohio, United States

Site Status

University of Cincinnati /ID# 14101

Cincinnati, Ohio, United States

Site Status

Nationwide Children's Hospital /ID# 21963

Columbus, Ohio, United States

Site Status

Legacy Emanuel Medical Center /ID# 14102

Portland, Oregon, United States

Site Status

St. Christopher's Hospital /ID# 24385

Philadelphia, Pennsylvania, United States

Site Status

Arthritis Associates of Kingsport /ID# 44462

Kingsport, Tennessee, United States

Site Status

Dr. Ramesh Gupta /ID# 45342

Memphis, Tennessee, United States

Site Status

Scott & White Health Care /ID# 36762

Round Rock, Texas, United States

Site Status

University of Utah /ID# 21041

Salt Lake City, Utah, United States

Site Status

Children's Speciality Center /ID# 11503

Burlington, Vermont, United States

Site Status

Seattle Children's Hospital /ID# 20968

Seattle, Washington, United States

Site Status

Children's Hospital Wisconsin - Milwaukee Campus /ID# 40226

Milwaukee, Wisconsin, United States

Site Status

Duplicate_Womens and Childrens Hospital /ID# 59182

Adelaide, South Australia, Australia

Site Status

Medizinische Universitaet Graz /ID# 26126

Graz, Styria, Austria

Site Status

Duplicate_Kepler Universitaetsklinikum GmbH /ID# 39068

Linz, Upper Austria, Austria

Site Status

Medizinische Universitaet Wien /ID# 26127

Vienna, Vienna, Austria

Site Status

Landeskrankenhaus Bregenz /ID# 26128

Bregenz, Vorarlberg, Austria

Site Status

Fakultni Nemocnice Brno /ID# 37343

Brno, , Czechia

Site Status

Revmatologicky ustav v Praze /ID# 43344

Prague, , Czechia

Site Status

Vseobecna fakultni nemocnice v Praze /ID# 47401

Prague, , Czechia

Site Status

Fakultni Nemocnice v Motole /ID# 37342

Prague, , Czechia

Site Status

Aarhus University Hospital /ID# 25445

Aarhus N, Central Jutland, Denmark

Site Status

Duplicate_Rigshospitalet, Finsen Centre /ID# 25444

Copenhagen, , Denmark

Site Status

CHU Strasbourg - Hopital de Hautepierre /ID# 25450

Strasbourg, Bas-Rhin, France

Site Status

Duplicate_CHU Bordeaux - Hopital Pellegrin /ID# 25454

Bordeaux, Gironde, France

Site Status

CHRU Tours - Hopital Bretonneau /ID# 27126

Tours, Indre-et-Loire, France

Site Status

CHRU Nancy - Hopitaux de Brabois /ID# 25452

Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

Site Status

CHRU Lille - Hopital Claude Huriez /ID# 25449

Lille, Nord, France

Site Status

CHU Toulouse /ID# 37347

Toulouse, Occitanie, France

Site Status

AP-HP - Hôpital Bicêtre /ID# 25443

Le Kremlin-Bicêtre, , France

Site Status

Duplicate_AP-HP - Hopital Cochin /ID# 37345

Paris, , France

Site Status

AP-HP - Hopital Necker /ID# 25442

Paris, , France

Site Status

Duplicate_CHU de Rennes - Hospital Sud /ID# 27123

Rennes, , France

Site Status

Universitaetsklinikum Tuebingen /ID# 39070

Tübingen, Baden-Wurttemberg, Germany

Site Status

Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 41623

Berlin, , Germany

Site Status

Helios Klinikum Berlin-Buch /ID# 37348

Berlin, , Germany

Site Status

Klinikum Bremen Mitte /ID# 45942

Bremen, , Germany

Site Status

Klinikum Dortmund gGmbH /ID# 44003

Dortmund, , Germany

Site Status

Center Rheumatology Child&Adol /ID# 39069

Garmisch-Patenkirchen, , Germany

Site Status

Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 39223

Hamburg, , Germany

Site Status

Klinikum St. Georg gGmbH /ID# 37349

Leipzig, , Germany

Site Status

Asklepios Klinik Sankt Augustin /ID# 41622

Sankt Augustin, , Germany

Site Status

Rheumazentrum Wedel /ID# 37350

Wedel, , Germany

Site Status

Children's Hosp P. A. Kyriakou /ID# 25448

Athens, Attica, Greece

Site Status

General Hospital of Thessaloniki Hippokrateio /ID# 25447

Thessaloniki, , Greece

Site Status

Debreceni Egyetem Klinikai Kozpont /ID# 95863

Debrecen, Hajdú-Bihar, Hungary

Site Status

Orszagos Reumatologiai es Fizioterapias Intezet /ID# 95095

Budapest, , Hungary

Site Status

Azienda Ospedaliero Universitaria Meyer /ID# 26123

Florence, Firenze, Italy

Site Status

IRCCS Ospedale Pediatrico Bambino Gesu /ID# 39074

Rome, Roma, Italy

Site Status

Duplicate_Azienda Ospedaliera Spedali Civili /ID# 39077

Brescia, , Italy

Site Status

Duplicate_Universita di Catania /ID# 39075

Catania, , Italy

Site Status

Ospedale Ss. Annunziata /ID# 37353

Chieti, , Italy

Site Status

Istituto Giannina Gaslini /ID# 26668

Genova, , Italy

Site Status

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 26124

Milan, , Italy

Site Status

Duplicate_Universita di Napoli Federico II /ID# 39078

Naples, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II /ID# 39072

Napoli, , Italy

Site Status

Fondazione IRCCS Policlinico /ID# 39076

Pavia, , Italy

Site Status

Universitair Medisch Centrum Utrecht /ID# 48842

Utrecht, , Netherlands

Site Status

Oslo Universitetssykehus, Radiumhospitalet /ID# 46402

Oslo, , Norway

Site Status

Hospital Garcia de Orta, EPE /ID# 37355

Almada, , Portugal

Site Status

Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 42682

Lisbon, , Portugal

Site Status

Centro Hospitalar Universitario do Porto, EPE - Hospital Santo Antonio /ID# 39081

Porto, , Portugal

Site Status

Centro de Reumatologia Pediatrico de Puerto Rico /Id# 61047

Bayamón, , Puerto Rico

Site Status

Puerto Rico Children Hospital /ID# 47742

Bayamón, , Puerto Rico

Site Status

Narodny ustav reumatickych chorob /ID# 38102

Piešťany, , Slovakia

Site Status

Hospital Sant Joan de Deu /ID# 37358

Esplugues de Llobregat, Barcelona, Spain

Site Status

Hospital Universitario Severo Ochoa /ID# 41751

Leganés, Madrid, Spain

Site Status

Hospital Universitario Vall d'Hebron /ID# 37357

Barcelona, , Spain

Site Status

Hospital Infantil Universitario Nino Jesus /ID# 37360

Madrid, , Spain

Site Status

Hospital Universitario Ramon y Cajal /ID# 41624

Madrid, , Spain

Site Status

Hospital Universitario y Politecnico La Fe /ID# 37359

Valencia, , Spain

Site Status

Queen Silvia Children's Hosp /ID# 26125

Gothenburg, Västra Götaland County, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Czechia Denmark France Germany Greece Hungary Italy Netherlands Norway Portugal Puerto Rico Slovakia Spain Sweden

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P10-262

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.